ATAI Life Sciences N.V. Proxy Statement Filed
Ticker: ATAI · Form: DEFA14A · Filed: Jun 18, 2025 · CIK: 1840904
| Field | Detail |
|---|---|
| Company | Atai Life Sciences N.V. (ATAI) |
| Form Type | DEFA14A |
| Filed Date | Jun 18, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, corporate-governance
TL;DR
ATAI Life Sciences proxy statement filed, no fee. Shareholders get info.
AI Summary
ATAI Life Sciences N.V. filed a DEFA14A proxy statement on June 18, 2025, related to the 6th annual HC Wainwright Neuro perspectives Conference. The filing indicates no fee was required for this submission. ATAI Life Sciences N.V. is incorporated in P7 with its fiscal year ending December 31.
Why It Matters
This filing provides shareholders with important information regarding the company's proxy voting process and corporate governance matters, which can influence investment decisions.
Risk Assessment
Risk Level: low — This is a routine proxy filing (DEFA14A) and does not contain new material financial or operational information that would inherently increase risk.
Key Players & Entities
- ATAI Life Sciences N.V. (company) — Registrant
- HC Wainwright (company) — Conference organizer
- Patrick Trucc (person) — Introducer at conference
FAQ
What is the purpose of a DEFA14A filing?
A DEFA14A filing is a proxy statement filed with the SEC by a company to solicit proxies from shareholders for an upcoming meeting, typically to vote on corporate matters.
When was this DEFA14A filed?
This DEFA14A filing was filed on June 18, 2025.
Is there a filing fee associated with this document?
No, the filing indicates that no fee was required for this submission.
What is ATAI Life Sciences N.V.'s fiscal year end?
ATAI Life Sciences N.V.'s fiscal year ends on December 31.
What industry does ATAI Life Sciences N.V. operate in?
ATAI Life Sciences N.V. operates in the Pharmaceutical Preparations industry, with SIC code 2834.
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on June 18, 2025 by Patrick Trucc regarding ATAI Life Sciences N.V. (ATAI).